หน้าแรก
ค้นหา
Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
แสดงข้อมูลเพิ่มเติม 1
Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer
MONARCH 2: Overall survival results from abermaciclib plus fulvestrant in HR+ HER2- advanced bre...
MONARCH 2: Overall survival of abemaciclib plus fulvestrant in HR+, HER2- advanced breast cancer
MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancer
George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial
Final overall survival analysis of MONARCH 1
Overall survival (OS) results of the Phase III MONALEESA-3 trial
#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...
Significance of the MONARCH 2 Findings for Abemaciclib in HR+/HER2- Breast Cancer
What are Progression Free Survival (PFS) and Overall Survival (OS)?
P-REALITY-X: Real-world, overall survival with palbociclib + aromatase inhibitor in HR+/HER2- MBC
MONARCH-2 Trial
Phase II Results for Abemaciclib in Pretreated HR+/HER2-Negative Breast Cancer
Final overall survival (OS) data from FLAURA trial
HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3
Overall survival results from MONALEESA-3 study on ribociclib plus fulvestrant in advanced breas...
Nadia Harbeck comments on MONARCH 2 & MONALEESA-3 trial results as game changers
Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer
MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence